Beta-Blocker Choice in Chronic Kidney Disease
In patients with chronic kidney disease (CKD) who have heart failure with reduced ejection fraction (HFrEF), a mortality-reducing beta-blocker should be selected from the guideline-proven agents rather than selecting specifically based on CKD status [1]. The 2022 AHA/ACC/HFSA guideline recommends using 1 of the 3 beta blockers proven to reduce mortality (bisoprolol, carvedilol, sustained-release metoprolol succinate) for HFrEF [1].
Medication Selection Algorithm
The beta-blockers with HFrEF mortality benefit are limited to the following options [1]:
- Carvedilol [1]
- Sustained-release metoprolol succinate [1]
- Bisoprolol [1]
Core Recommendation
For CKD patients with HFrEF, either carvedilol or sustained-release metoprolol succinate is guideline-recommended based on heart failure evidence rather than CKD-specific preference [1]. The recommended selection is supported by the guideline Class I, Level A recommendation for HFrEF beta-blocker therapy using 1 of these 3 agents [1].
Initiation Thresholds and Indications
Beta-blocker therapy is indicated in HFrEF in patients with current or previous symptoms to reduce mortality and hospitalizations [1]. CKD does not replace the heart failure indication or change the guideline beta-blocker selection set [1].
Important Clarifications in CKD
KDIGO materials on heart failure in CKD use beta-adrenergic blockade options that include carvedilol and metoprolol (tartrate/ bisoprolol category) within an overall CKD heart failure pharmacotherapy framework [2]. KDIGO materials do not establish a carvedilol-versus-metoprolol preferential rule based on CKD alone [2].
Common Pitfalls to Avoid
Selecting a beta-blocker outside the guideline-proven HFrEF mortality-reducing set (carvedilol, sustained-release metoprolol succinate, bisoprolol) risks loss of guideline-directed outcome benefit in HFrEF [1].
Treatment Targets
Beta-blocker selection is based on HFrEF outcome evidence using the guideline-proven agents rather than on a CKD-specific target beta-blocker [1].